Sapropterin Dipharma now available in Europe

3 July 2023
dipharma-big

Swiss generic drugmaker Dipharma today announced that its product Sapropterin Dipharma is now available in main European countries including in Switzerland.

Sapropterin Dipharma is available in the form of soluble tablets 100mg, powder for oral solution 100mg and powder for oral solution 500mg. The product is made in Switzerland with key supplies all manufactured in Europe, complying with the most stringent European environmental and safety standards.

Sapropterin Dipharma is a generic equivalent to US biotech BioMarin Pharmaceutical’s (Nasdaq: BMRN) Kuvan (sapropterin dihydrochloride), which generated sales of $227.6 million last year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics